Control of the ratio of LAP to LIP
OwnerYohei Hiraiinventor
Life of this patent
Estimating the term…
Abstract
The present invention provides recombinant gene vectors and nucleic acid constructs which are capable of decreasing, reducing or suppressing the transcription/translation of LIP (transcription inhibitor protein), and in some examples, without affecting the transcription/translation of LAP (transcription activator). Such vectors and constructs are used in methods for increasing the ratio of LAP to LIP activity in a cell and for treating and/or ameliorating the symptoms of a disease or condition associated with the ratio of LAP to LIP. The present invention also provides methods for screening for agents that are capable of modifying the ratio of LAP to LIP activity in a cell or individual.
Claims45
A recombinant vector encoding LAP (transciptional activator) activity wherein expression of LIP activity is inhibited, and wherein expression of LIP activity is inhibited such that LIP does not down-regulate LAP activity.
A variant LAP polypeptide comprising a substitution of the initiating codon, ATG, of LIP with another codon, wherein the substituted codon is not TTG.
An oligonucleotide comprising a nucleotide sequence of about 10 to about 100 nucleotides in length from around the initiation codon, ATG, of LIP (transcription inhibitor protein) in the nucleotide sequence of a C/EBPβ gene, or a complementary sequence thereof, wherein said oligonucleotide, or a complementary sequence thereof, is capable of reducing LIP expression.
A method of screening whether an agent modulates the ratio of the expression level of LAP (transcription activator) to LIP (transcription inhibitor protein) which are expressed from a C/EBPβ gene comprising the step of contacting the C/EBPβ gene with said agent and measuring the ratio of LAP expression to LIP expression.
A method for treating and/or ameliorating the symptoms of a disease and/or condition associated with an abnormal ratio of the expression level of LAP (transcription activator) to LIP (transcription inhibitor protein) in an individual comprising administering to the individual a recombinant vector encoding LAP activity wherein expression of LIP activity is inhibited.
Dependencies are inferred from the claim text.